Company Analysis
Sign in

Cardiol Therapeutics Inc. (CRDL)

Nasdaq: CRDL · Biological Products, (No Diagnostic Substances) · Oakville, ON · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.3
◀ Past 6.1● Present 3.6▶ Future 6.4
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In Canadian dollars (CAD), as filed; per-share figures in Canadian dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedMar 31, 2026Mar 31, 2025Apr 1, 2024Mar 29, 2023Mar 24, 2022·
Revenue····78,760·
Research and development14,018,46114,012,13014,224,28718,962,08010,870,42110,602,851
General and administrative20,297,83526,264,52115,561,21722,373,79827,873,14010,087,610
Operating income-34,316,296-40,276,651-29,785,504-41,335,878-38,664,801-20,690,461
Interest income726,4011,193,3422,038,4651,237,632106,00176,583
Income tax expense···000
Net income-33,818,874-36,677,299-28,128,292-30,930,647-31,638,244-20,640,935
Net income to ordinary shareholders····-31,638,244-20,640,935
Earnings per share, basic-0.39-0.51-0.44-0.49-0.73-0.69
Earnings per share, diluted-0.39-0.51-0.44-0.49-0.73-0.69
Weighted average shares, basic86,989,33971,567,75564,463,08762,505,98243,222,81929,857,136
Weighted average shares, diluted86,989,33971,567,75564,463,08762,505,98243,222,81929,857,136
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldifrs-full:Revenue
Research and development spent on inventing what it sells nextifrs-full:ResearchAndDevelopmentExpense
General and administrative the cost of running the company itselfifrs-full:GeneralAndAdministrativeExpense
Operating income profit from running the business, before interest and taxifrs-full:ProfitLossFromOperatingActivities
Interest income what its cash and investments earnedifrs-full:RevenueFromInterest
Income tax expense tax charged on the period's profitifrs-full:IncomeTaxExpenseContinuingOperations
Net income the whole group's profit, minority holders' share includedifrs-full:ProfitLoss
Net income to ordinary shareholders what is left for common shareholdersifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
Earnings per share, basic net income per share outstandingifrs-full:BasicEarningsLossPerShare
Earnings per share, diluted net income per share, counting every share that could be issuedifrs-full:DilutedEarningsLossPerShare
Weighted average shares, basic the average count of shares outstandingifrs-full:WeightedAverageShares
Weighted average shares, diluted the average count with every share that could be issuedifrs-full:AdjustedWeightedAverageShares
SI Assistanton CRDL · research, not advice